Young adults with type 2 diabetes mellitus (T2DM) are frequently underrepresented in clinical trials despite a longer expected lifetime exposure to hyperglycemia and cardiometabolic risk. In a post hoc analysis published in Diabetes, Obesity and Metabolism, semaglutide reduced glycated hemoglobin (HbA1c) and body weight across all evaluated age groups, including adults aged 40 years or younger.

The analysis used pooled data from the SUSTAIN program of once-weekly subcutaneous semaglutide trials and the PIONEER program of once-daily oral semaglutide trials. Efficacy outcomes were assessed across three age categories at study enrollment: 40 years or younger, older than 40 to 50 years, and older than 50 years.

Across both programs, semaglutide treatment reduced HbA1c levels and body weight versus placebo or active comparators in all age subgroups. Reductions were particularly notable in younger adults compared with the older age categories.

Safety analyses evaluated serious adverse events and gastrointestinal severe adverse events. The proportion of participants with serious adverse events was generally comparable between semaglutide and comparator groups across age subgroups and routes of administration.

The findings suggest semaglutide provides consistent glycemic and body weight benefits across adult age groups with T2DM, including younger adults. Effective early treatment of younger-onset T2DM may help reduce long-term diabetes-related complications.